Nanjing IASO Bio Raises $60 Million in B Round for Cell Therapies
publication date: Mar 23, 2020
Nanjing IASO Biotherapeutics completed a $60 million Series B financing led by GL Ventures, a Hillhouse Capital VC focusing on early-stage innovative companies. Founded in 2017, IASO is developing cell therapies for oncology conditions, with more than 10 pipeline products led by autologous and universal CAR-T products for hematological tumors. It is also working on novel TCR-like CAR-T cell therapies for solid tumor indications. Last year, IASO and Innovent announced their anti-BCMA CAR-T produced a 100% overall response rate in patients with relapsed/refractory multiple myeloma. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.